AI-based Drug Re-innovation
BioXcel Therapeutics, Inc. is a
biopharmaceutical company developing transformative medicines in neuroscience utilizing artificial intelligence.
Innovative Medicine
Backed by the
Power of AI
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.
Innovative Medicine
Backed by the Power of AI
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.
Our Approach to Drug Development
- Optimizes R&D economics
- Shortens development timelines
- Increases probability of success
May 09, 2024
BioXcel Therapeutics Reports First Quarter 2024 Financial ResultsVIEW RELEASE
Apr 25, 2024
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024VIEW RELEASE
Apr 24, 2024
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual MeetingVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
May 09, 2024 01:14 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
2.35
CHANGE
0.23 (10.85%)